Tara Lynn Kieffer
Chief Operating OfficerDr. Tara Lynn Kieffer, Ph.D., was Chief Product Strategy Officer of Enanta Pharmaceuticals, Inc. since January 1, 2024 until 2026 and serves as Chief Operating Officer since October 28, 2026. Dr. Kieffer served as the Senior Vice President of New Product Strategy and Development at Enanta Pharmaceuticals, Inc since joining in December 2020 until January 1, 2024. She has virologic research and pharmaceutical industry experience, with proven expertise in drug discovery and development, program management and business development, including having played significant roles in developing and launching medicines for infectious and rare diseases. Dr. Kieffer joins Enanta from Vertex Pharmaceuticals Inc. where she held roles of increasing responsibility, most recently, she was Vice President, External Innovation, Business Development since October 2018 where she was responsible for assessing the external innovation landscape and leading projects aimed at identifying in-licensing and acquisition opportunities Prior to that she was Vice President, Integrated Program Management since March 2017 and Senior Director, Chief of Staff to the Chief Medical Officer from October 2014 to March 2017. In her previous ten years at Vertex she advanced as a virologist, becoming Director, Clinical Biomarkers in the Department of Translational Medical Sciences. Earlier in her career, Dr. Kieffer was Director, Clinical Biomarkers within the Translational and Medical Sciences Department. Prior to that role, she was Head of Clinical Virology, where she built and led a team responsible for laboratory and clinical research studies to understand the development of antiviral drug resistance to Hepatitis C and influenza viruses. Dr. Kieffer did her graduate work at Johns Hopkins School of Medicine, Department of Molecular Biology and Genetics from 1999 to 2004. She is co-author on more than 50 publications and an inventor on multiple patents involving treatments for Hepatitis C. Dr. Kieffer is a summa cum laude graduate of Colgate University with a B.A. in Molecular Biology. She holds a Ph.D. in Immunology from Johns Hopkins School of Medicine.
Positions
- Company NameEnanta Pharmaceuticals, Inc.Stock CodeENTAPositionChief Operating OfficerColleagues
- JRJay R. LulyPresident, CEO & Director
- BLBruce Leonard Andrews CarterIndependent Non-Executive Chairman
- YSYat Sun OrChief Scientific Officer
- STScott T. RottinghausChief Medical Officer
- HRHarry R. TroutVP of Finance & Interim Principal Financial Officer
- TCTerry C. VanceIndependent Director
- KPKristine PetersonIndependent Director
- MGMark G. FolettaIndependent Director
